@invstify.com

1 day ago

Why did Hoffman Michael B (Executive) just buy $1.5M of $ANVS (Annovis Bio, Inc.)?
8 buys vs 0 sells in the last year.

Track: invstify.com/stock/ANVS

#InsiderTrading #ANVS #StockMarket

StockTitan

@stocktitan.net

4 days ago

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections Annovis (NYSE: ANVS) announced issuance of U.S. Patent No. 12,582,632 B2 for buntanetap covering prevention and treatment of neurological injuries caused by brain infections. The patent covers administration across viral, bacterial, fungal, protozoan and parasitic agents, includes preventive and reversal claims, and extends through 2044.The company is a Phase 3 clinical-stage developer of buntanetap for neurodegenerative diseases.

#ANVS Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

www.stocktitan.net/news/ANVS/annovis-secure...

StockTitan

@stocktitan.net

6 days ago

From execution poison to Alzheimer’s drug: Annovis traces buntanetap The review arrives as Annovis enrolls patients in two studies: its pivotal Phase 3 trial in early Alzheimer’s is 70% enrolled, and its Parkinson’s extension is 20%.

#ANVS Annovis Publishes Historical Review of Buntanetap in The Scientist

www.stocktitan.net/news/ANVS/annovis-publis...

StockTitan

@stocktitan.net

2 weeks ago

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's

#ANVS Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

www.stocktitan.net/news/ANVS/annovis-partne...

Stichting Laka

@laka.org

1 month ago

Kernafval-lekage bij NRG-Pallas onthult gebrekkig beheer In oktober 2024 merkte NRG bij het verwerken van vaatjes met historisch kernafval dat er water in het pluggennest van de Waste Storage Facility stond  (het pluggennest in de WSF is een stelsel van verticale ondergrondse pijpen waarin kernafvalvaten zijn opgestapeld). Na deze melding bleef het lang s

Kernafval-lekage bij NRG-Pallas onthult gebrekkig beheer
#ANVS #Decentraal_on_site #NRG_Pallas #Radioactief_afval #INES #MOG #RWMP #Waste_Storage_Facility

StockTitan

@stocktitan.net

1 month ago

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference Annovis (NYSE: ANVS) announced two presentations at AD/PD™ 2026 in Copenhagen, March 17-21, 2026, covering clinical data for buntanetap in Parkinson’s disease and an update on the pivotal Phase 3 trial in early Alzheimer’s disease.Presenters and session IDs: Presentation #3581 on PD cognition/biomarkers and Presentation #3582 on a 6- and 18-month randomized Phase 3 trial in early AD, both presented by Cheng Fang, Ph.D.

#ANVS Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

www.stocktitan.net/news/ANVS/annovis-announ...

Stichting Laka

@laka.org

2 months ago

Veel kritische vragen over levensduurverlenging Borssele Partijen in de Tweede kamer hebben veel vragen over het wetsvoorstel voor  de tweede levensduurverlenging van kerncentrale Borssele, nu al ruim 50 jaar oud. Het voorstel schrapt de huidige einddatum van 31 december 2033 uit de Kernenergiewet, en maakt het mogelijk dat exploitant EPZ opnieuw een verg

Veel kritische vragen over levensduurverlenging Borssele
#ANVS #Borssele #D66 #GroenLinks_PvdA #Parlement #EPZ #PLEX

Small Cap Strategist

@smcapstrategist.bsky.social

3 months ago

Charts of the Day - small-cap stocks forming falling three methods candlestick signal, Tue Dec 23rd - #ANVS #NKLR - More: crystalequityresearch.com/charts-of-th... - #smallcap

StockTitan

@stocktitan.net

3 months ago

Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients Annovis (NYSE: ANVS) will begin an Open-Label Extension (OLE) study for Parkinson's disease in January 2026 to evaluate long-term safety and efficacy of buntanetap.Key design: enrollment target 500 patients across U.S. sites, 36-month once-daily 30 mg treatment, two cohorts (invited former study participants and patients with deep brain stimulation). Skin and plasma biomarkers will be collected.The OLE is intended to help meet FDA patient-exposure criteria toward NDA readiness by contributing to a ~1,500 treated-patient target and required multi-duration exposure thresholds.

#ANVS Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

www.stocktitan.net/news/ANVS/annovis-announ...

Market Wire News

@marketwirenews.com

3 months ago

BREAKING NEWS: ( NYSE: #ANVS ) InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session

Stichting Laka

@laka.org

4 months ago

Europese toezichthouders reviewen achterhaalde NUWARD-SMR Zes Europese nucleaire toezichthouders, waaronder de Nederlands ANVS, hebben na drie jaar een gezamenlijke veiligheidsreview van een Frans SMR-ontwerp afgerond. EDF, de ontwerper, had juist dat ontwerp in 2024 echter als onhaalbaar in de prullenbak gegooid. De nu afgeronde Joint Early Review van die

Europese toezichthouders reviewen achterhaalde NUWARD-SMR
#ANVS #EdF #Nuward #SMRs

Market Wire News

@marketwirenews.com

4 months ago

JUST IN: ( NYSE: #ANVS ) InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting

StockTitan

@stocktitan.net

4 months ago

#ANVS Annovis Announces Two Presentations at the CTAD 2025 Conference

www.stocktitan.net/news/ANVS/annovis-announ...

Market Wire News

@marketwirenews.com

4 months ago

BREAKING NEWS: ( NYSE: #ANVS ) InvestorNewsBreaks - Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson's Disease Dementia Program

StockTitan

@stocktitan.net

4 months ago

Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study Annovis (NYSE: ANVS) announced the FDA scheduled a Type C meeting in January 2026 to discuss the clinical development pathway for buntanetap in Parkinson's disease dementia (PDD). The company said the meeting will cover trial design, patient population, and a potential approval route.Annovis also reaffirmed that its Phase 3 Alzheimer's disease trial is enrolling on plan with full FDA alignment on study design, endpoints, and population following an End-of-Phase 2 meeting in 2024. Management said the Phase 3 design could support two NDAs: one for symptomatic treatment and one for disease-modifying treatment.

#ANVS Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

www.stocktitan.net/news/ANVS/annovis-announ...

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Most searched small-cap stocks, Mon Nov 17th - #RXRX #LAC #SGBX #HIVE #ANVS #SGML #IVVD #DNN #LAES #CYPH #ZYME #WRD #QUBT #PLUG #PEBO #ONDS #OBE #ESPR #CLSK #AI - More: crystalequityresearch.com/most-searche... - #smallcap

StockTitan

@stocktitan.net

4 months ago

#ANVS Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

www.stocktitan.net/news/ANVS/annovis-report...

StockTitan

@stocktitan.net

4 months ago

#ANVS Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ANVS/annovis-provid...

StockTitan

@stocktitan.net

5 months ago

#ANVS Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

www.stocktitan.net/news/ANVS/annovis-achiev...

Stichting Laka

@laka.org

5 months ago

WISE en Greenpeace uiten zorgen over veiligheidsevaluatie kerncentrale Borssele In een gezamenlijke zienswijze hebben WISE en Greenpeace stevige kritiek geuit op de consultatieprocedure rond de veiligheidsevaluatie van kerncentrale Borssele. Ze stellen dat de huidige aanpak van de Autoriteit Nucleaire Veiligheid en Stralingsbescherming (ANVS) tekortschiet in transparantie, juri

WISE en Greenpeace uiten zorgen over veiligheidsevaluatie kerncentrale Borssele
#ANVS #Borssele #10EVA #Greenpeace #Milieueffectrapportage #PLEX #WISE

Stichting Laka

@laka.org

5 months ago

Zinkgat bij kernreactor Petten De ANVS heeft gisteren  een melding ontvangen van NRG PALLAS, de vergunninghouder van de Hogefluxreactor (HFR) in Petten. Nabij de secundaire koelwaterleiding van de HFR naar de Noordzee is een zinkgat ontstaan. Deze koelwaterleiding bevat water uit het Noordhollandsch Kanaal. NRG PALLAS onderzoekt

Zinkgat bij kernreactor Petten
#ANVS #HFR #NRG_PALLAS #Ongelukken #Veiligheid #koelwater

StockTitan

@stocktitan.net

5 months ago

Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules Annovis Bio (NYSE: ANVS) announced a registered direct offering of 1,670,732 shares of common stock at $2.05 per share (closing price on Oct 24, 2025).The offering is expected to close on or about October 28, 2025, with aggregate gross proceeds of approximately $3.4 million before placement agent fees and expenses. Michael Hoffman (board chair) and CEO Dr. Maria Maccecchini are participating in the purchase.H.C. Wainwright & Co. is the exclusive placement agent. Net proceeds are intended for working capital and general corporate purposes. Securities are offered under a Form S-3 shelf registration (No. 333-276814) declared effective Feb 12, 2024.

#ANVS Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules

www.stocktitan.net/news/ANVS/annovis-announ...

StockTitan

@stocktitan.net

5 months ago

Annovis Announces $6 Million Registered Direct Offering of Common Stock Annovis (NYSE: ANVS) entered into definitive agreements to sell an aggregate of 4,000,000 shares of common stock (or pre-funded warrants) at $1.50 per share in a registered direct offering, with expected gross proceeds of approximately $6 million. Closing is expected on or about October 13, 2025, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The offering is being made under a shelf registration (Form S-3, Reg. No. 333-276814) with a prospectus supplement to be filed with the SEC.

#ANVS Annovis Announces $6 Million Registered Direct Offering of Common Stock

www.stocktitan.net/news/ANVS/annovis-announ...

StockTitan

@stocktitan.net

5 months ago

Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment Annovis (NYSE: ANVS) reported novel biomarker results from its Phase 2/3 Alzheimer's study (NCT05686044) showing that buntanetap reduced inflammatory markers IL-5, IL-6, S100A12, IFN-γ, IGF1R and lowered NFL after three months. Responses were seen in all patients with positive pTau217, including mild and moderate stages. Company cites prior cognitive benefit in mild AD and notes buntanetap is being evaluated in a pivotal Phase 3 early AD trial (NCT06709014) with a 6-month symptomatic readout and an 18-month disease-modification readout. Full biomarker data will be presented at CTAD Dec 1-4, 2025.

#ANVS Annovis Announces Novel Biomarker Data in Alzheimer’s Patients Supporting Buntanetap’s Potential as a Disease-Modifying Treatment

www.stocktitan.net/news/ANVS/annovis-announ...